Search results
Results from the WOW.Com Content Network
Despite this, the available evidence suggests it is safe during pregnancy, although the evidence is insufficiently strong to say anything with a high degree of confidence. [37] Olanzapine is associated with weight gain, which according to recent studies, may put olanzapine-treated patients' offspring at a heightened risk for neural tube defects ...
Bradycardia (low heart rate) QTc interval prolongation (an abnormality in the electrical cycle of the heart) Photosensitivity reaction; Alopecia (hair loss) Urinary incontinence; Urinary retention, the inability to urinate. Amenorrhea the cessation of menses (a woman's menstrual cycles). This is a complication of hyperprolactinaemia.
The fundamental goal of treatment should be the prevention of the important endpoints of hypertension, such as heart attack, stroke and heart failure. Patient age, associated clinical conditions and end-organ damage also play a part in determining dosage and type of medication administered. [ 3 ]
One change you can make that can immediately improve your heart attack risk, according to Dr. Sandeep R. Singh, MD, MBA, a cardiologist and medical advisor to Recovery Plus, is eating a healthy ...
The study, published Thursday in the Journal of the American Heart Association, found that people who reported extreme pain a year after their heart attack – even pain that was not associated ...
Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine. [9] Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring. [9]
Even if you’ve never smoked a cigarette in your life, you aren’t off the hook for being completely risk-free of experiencing a heart attack. “The risk of a heart attack increases with age ...
Grade 1 hypertension. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, also known as ALLHAT, was a randomized, double-blind, active-controlled study comparing at the same time, four different classes of antihypertensive drugs with the rate of coronary heart disease (CHD) events in ‘high-risk’ people with hypertension. [1]